Nisha Pandey

Health and Me

21% In 80 Weeks: Lancet Study Finds Lilly’s Retatrutide Delivers One Of The Biggest Weight Losses Ever

New Triple-Action Weight-Loss Drug Helps Diabetics Lose 21% Body Weight: What The Lancet Study Found

<span>Eli Lilly</span>’s highly anticipated GLP-1 weight-loss drug <span>retatrutide</span> has delivered nearly 21% average weight loss in people with type 2 diabetes and obesity, according to results from a large Phase 3 trial published in <em>The <span rel="noindex">Lancet</span></em>. In an ever-expanding weight loss medication market, retatrutide is already showing significant promise in obesity and diabetes management. 

The drug, retatrutide, is being developed by Eli Lilly and is not approved by the <span>FDA</span> yet. In the TRIUMPH-2 trial, people receiving the highest 12 mg dose lost an average of 20.8% of their body weight over 80 weeks, equivalent to about 49.6 pounds or 22.5 kg. 

The findings about <a href="https://www.healthandme.com/health-news/retatrutide-warning-experts-flag-rise-of-fake-weight-loss-jabs-being-sold-online-article-153236293" data-type="tilCustomLink">retatrutide's</a> trial were presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan and published simultaneously in <em>The Lancet</em>. 

<h2>How Is Retatrutide Different From Other GLP-1 Drugs? </h2>

Retatrutide is a triple agonist because it activates three hormone receptors:

<ul><li><span rel="noindex">GIP</span></li><li>GLP-1</li><li>Glucagon</li></ul>

<a href="https://www.healthandme.com/fitness/zepbound-mounjaro-may-do-more-than-suppress-appetite-study-finds-calorie-burning-effect-article-156235292" data-type="tilCustomLink">GLP-1-based medicines</a> are already widely used for diabetes and obesity. Retatrutide activates GIP and glucagon pathways as well, creating a three-way approach to manage appetite, blood sugar and metabolism. The drug is given once weekly by injection and remains experimental and investigational.

Also read: <a href="https://www.healthandme.com/health-news/world-heart-day-you-feel-healthy-but-plaque-may-already-be-building-in-your-arteries-in-your-20s-article-156246734" data-type="tilCustomLink">World Heart Day: You Feel Healthy. But Plaque May Already Be Building In Your Arteries In Your 20s</a>

<h2>Retatrutide Weight Loss Results </h2>

TRIUMPH-2 included adults with obesity or overweight and type 2 diabetes. Participants receiving retatrutide were assigned to 4 mg, 9 mg or 12 mg doses and followed for 80 weeks. The average weight loss was:

<ul><li>4 mg: 12.7%</li><li>9 mg: 19.1%</li><li>12 mg: 20.8%</li><li>Placebo: 4.0% </li></ul>

The response was even greater among participants who started the study with a <span>BMI</span> of at least 35. Those receiving 12 mg lost an average of 23.4% of their body weight, or about 60.8 pounds.

By week 80, 59.5% of people taking 12 mg no longer met the BMI criteria for <a href="https://www.healthandme.com/health-news/stopping-ozempic-wegovy-mounjaro-linked-to-22-higher-heart-attack-stroke-risk-study-article-156211503" data-type="tilCustomLink">obesity</a>.

Also read: <a href="https://www.healthandme.com/health-wellness/100-blockage-at-18-25-patients-under-40-on-world-heart-day-cardiologists-reveal-an-alarming-heart-attack-pattern-article-156243737" data-type="tilCustomLink">100% Blockage At 18, 25% Patients Under 40: On World Heart Day, Cardiologists Reveal An Alarming Heart Attack Pattern</a> 

Retatrutide not only led to one of the biggest weight losses ever seen, it also improved HbA1c, a measure of average blood glucose over the previous two to three months. At 80 weeks, HbA1c fell by:

<ul><li>1.4 percentage points with 4 mg</li><li>1.6 percentage points with 9 mg</li><li>1.5 percentage points with 12 mg</li></ul>

Up to 40% of participants receiving retatrutide achieved an HbA1c below 5.7%, which is within the normal range. 

Statins for High Cholesterol Explained: Who Needs Them, Side Effects & Long-Term Use

The results are certainly seem promising, particularly as people with type 2 diabetes can sometimes lose less weight with obesity medicines than people without <a href="https://www.healthandme.com/health-news/from-365-shots-to-52-how-could-lillys-newly-approved-weekly-insulin-injection-change-diabetes-care-article-156238125" data-type="tilCustomLink">diabetes</a>. 

Retatrutide's combination of substantial weight loss and improved blood sugar control makes it an important drug to watch in a competitive <a href="https://www.healthandme.com/health-news/hundreds-of-american-glp-1-users-sue-novo-nordisk-eli-lilly-over-vision-loss-what-is-naion-article-156200838" data-type="tilCustomLink">GLP-1 market</a>.

Since it's not approved yet, more evidence will be needed on its long-term safety, cardiovascular effects and how its benefits compare with existing treatments. It is also worth remembering that the 20.8% figure represents an average, not the amount every participant lost.

Retatrutide's development is a sign that obesity and diabetes treatment is extending beyond just managing blood sugar. The next generation of drugs is all about targeting weight, glucose and metabolism together.

Health Conditions A-Z

health

new-triple-action-weight-loss-drug-helps-diabetics-lose-21-body-weight-what-the-lancet-study-found

retatrutide

eli lilly

lancet

glp 1

10-times-stronger-than-fentanyl-officials-say-this-opioid-has-now-been-detected-across-every-region-of-the-us

10 Times Stronger Than Fentanyl: Officials Say This Opioid Has Now Been Detected Across Every Region Of The US

good-morning-americas-will-reeve-says-he-dismissed-testicular-cancer-initially-what-are-the-early-signs

Good Morning America's Will Reeve Says He Dismissed Testicular Cancer Initially: What Are The Early Signs

Fitness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Eli Lilly’s highly anticipated GLP-1 weight-loss drug retatrutide has delivered nearly 21% average weight loss in people with type 2 diabetes and obesity, according to results from a large Phase 3 trial published in The Lancet. In an ever-expanding weight loss medication market, retatrutide is already showing significant promise in obesity and diabetes management. The drug, retatrutide, is being developed by Eli Lilly and is not approved by the FDA yet. In the TRIUMPH-2 trial, people receiving the highest 12 mg dose lost an average of 20.8% of their body weight over 80 weeks, equivalent to about 49.6 pounds or 22.5 kg. The findings about retatrutide's trial were presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan and published simultaneously in The Lancet. How Is Retatrutide Different From Other GLP-1 Drugs? Retatrutide is a triple agonist because it activates three hormone receptors:GIPGLP-1GlucagonGLP-1-based medicines are already widely used for diabetes and obesity. Retatrutide activates GIP and glucagon pathways as well, creating a three-way approach to manage appetite, blood sugar and metabolism. The drug is given once weekly by injection and remains experimental and investigational.Also read: World Heart Day: You Feel Healthy. But Plaque May Already Be Building In Your Arteries In Your 20sRetatrutide Weight Loss Results TRIUMPH-2 included adults with obesity or overweight and type 2 diabetes. Participants receiving retatrutide were assigned to 4 mg, 9 mg or 12 mg doses and followed for 80 weeks. The average weight loss was:4 mg: 12.7%9 mg: 19.1%12 mg: 20.8%Placebo: 4.0% The response was even greater among participants who started the study with a BMI of at least 35. Those receiving 12 mg lost an average of 23.4% of their body weight, or about 60.8 pounds.By week 80, 59.5% of people taking 12 mg no longer met the BMI criteria for obesity.Also read: 100% Blockage At 18, 25% Patients Under 40: On World Heart Day, Cardiologists Reveal An Alarming Heart Attack Pattern Retatrutide Blood Sugar ResultsRetatrutide not only led to one of the biggest weight losses ever seen, it also improved HbA1c, a measure of average blood glucose over the previous two to three months. At 80 weeks, HbA1c fell by:1.4 percentage points with 4 mg1.6 percentage points with 9 mg1.5 percentage points with 12 mgUp to 40% of participants receiving retatrutide achieved an HbA1c below 5.7%, which is within the normal range. The Next Big Weight-Loss Drug?      The results are certainly seem promising, particularly as people with type 2 diabetes can sometimes lose less weight with obesity medicines than people without diabetes. Retatrutide's combination of substantial weight loss and improved blood sugar control makes it an important drug to watch in a competitive GLP-1 market.Since it's not approved yet, more evidence will be needed on its long-term safety, cardiovascular effects and how its benefits compare with existing treatments. It is also worth remembering that the 20.8% figure represents an average, not the amount every participant lost.Retatrutide's development is a sign that obesity and diabetes treatment is extending beyond just managing blood sugar. The next generation of drugs is all about targeting weight, glucose and metabolism together.